Field Medical Taps Med-Tech Veteran to Steer Next-Gen Arrhythmia Tech

CARDIFF-BY-THE-SEA, CA – March 16, 2026 – Field Medical, a clinical-stage company at the forefront of cardiac arrhythmia treatment, has appointed Dr. Mark A. Turco as its new chief executive officer. The move signals a strategic acceleration for the company as it advances its second-generation pulsed field ablation (PFA) technology through crucial clinical and regulatory milestones. Dr. Turco, a seasoned executive with a unique background as an interventional cardiologist and a proven leader in the medical device industry, takes the helm at a pivotal time for the company and the rapidly evolving PFA market.

A Leader with a Strategic Playbook

Dr. Turco brings over three decades of experience that uniquely bridges the gap between clinical practice and corporate strategy. His appointment is seen by industry observers as a deliberate move to install a leader with a track record of navigating complex medical technologies from development to high-value commercial success.

His most recent major success was as president and CEO of JC Medical, Inc., a company developing a novel transcatheter aortic valve replacement (TAVR) system. Under his leadership, JC Medical was acquired by industry giant Edwards Lifesciences in July 2024 in a deal valued at up to $320 million, a testament to his ability to guide an innovative technology toward a successful strategic transaction. Before that, Dr. Turco held senior executive roles at Medtronic and Covidien, where he served as vice president and chief medical officer for their vascular and neurovascular franchises. In these positions, he was instrumental in shaping clinical strategy, evaluating new technologies, and driving growth for major product platforms.

"Mark's unique background as a cardiologist, clinical trialist and an experienced medical device executive equips him well to guide Field Medical through this next phase of growth," said Ben Cannon, a board member of Field Medical representing investors BioStar Capital and Cue Growth. "As we accelerate our clinical programs and strengthen our operational capabilities, his executive experience in advancing complex medical technologies across development, regulatory and commercialization milestones will enable disciplined execution and sustainable long-term value creation."

Differentiating in a Crowded PFA Arena

Dr. Turco joins Field Medical as the market for pulsed field ablation is exploding. PFA is a disruptive technology that uses non-thermal electric fields to ablate, or destroy, heart tissue causing arrhythmias. Its key advantage is tissue selectivity—it primarily affects heart muscle cells while sparing adjacent structures like the esophagus and phrenic nerve, a significant safety improvement over traditional thermal ablation methods.

The global PFA market, valued at over $1.7 billion in 2024, is projected to surge past $15 billion by 2034. This rapid growth has attracted major players, with Medtronic, Boston Scientific, and Johnson & Johnson's Biosense Webster all securing FDA approvals for their PFA systems to treat atrial fibrillation (AFib), the most common arrhythmia.

In this competitive landscape, Field Medical is carving out a distinct niche. The company positions its FieldForce™ Ablation System as a "second-generation" solution designed to tackle not only AFib but also the more complex and life-threatening ventricular arrhythmias, specifically scar-related ventricular tachycardia (VT). The system’s proprietary FieldBending™ technology is engineered to alter the shape of the electric field, enabling the creation of deeper and more contiguous lesions. This is particularly critical in the thick, scarred tissue of the ventricles where traditional ablation often falls short.

Breakthrough Status and Clinical Validation

Field Medical's focus on this challenging patient population has already earned it significant regulatory and clinical validation. In 2024, the FDA granted the FieldForce system Breakthrough Device Designation for its VT indication and accepted it into the Total Product Life Cycle Advisory Program (TAP) Pilot. These designations are reserved for technologies that have the potential to provide more effective treatment for life-threatening conditions and are intended to expedite the review and development process, signaling the FDA's recognition of the technology’s promise.

This promise was substantiated by compelling clinical data. In October 2025, the results of the VCAS first-in-human trial were published in the prestigious journal Circulation. The study evaluated the FieldForce system in 26 patients with complex, scar-related VT. The results were highly encouraging: acute procedural success was achieved in 92% of patients, and at six months, over 81% remained free from recurrent VT or related defibrillator shocks.

Most significantly, the trial demonstrated a 98% reduction in the overall burden of VT episodes and, in a key sub-study, proved the system's ability to create transmural, or full-thickness, lesions in the ventricular scar tissue. This has long been the "holy grail" of VT ablation, and achieving it with a non-thermal energy source represents a potential paradigm shift in care for these high-risk patients.

This combination of a differentiated technology, strong clinical evidence, and a clear regulatory path has fueled robust investor confidence. The company successfully closed a $40 million Series A financing round in early 2025, followed by an oversubscribed $35 million Series B round co-led by BioStar Capital and Cue Growth. This capital provides the necessary runway for Dr. Turco to execute on the company’s ambitious goals, including the completion of further clinical trials and scaling operations for commercial readiness.

"I am honored to join Field Medical at this pivotal moment in its evolution," Dr. Turco stated in the company’s announcement. "The company has built a differentiated PFA platform with the potential to meaningfully address significant unmet patient needs in both ventricular arrhythmias and atrial fibrillation. I look forward to partnering closely with the exceptional Field Medical team to rigorously advance our clinical programs and navigate regulatory pathways to meet our operational goals."

With a seasoned leader at the helm, a validated technology targeting a critical unmet need, and strong financial backing, Field Medical is poised to make its mark on the future of cardiac ablation. The company’s progress will be closely watched by clinicians and competitors alike as it works to bring its next-generation solution to patients suffering from some of the most challenging heart rhythm disorders.